New Zealand markets closed

NVS Jan 2024 110.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.70000.0000 (0.00%)
As of 10:45AM EDT. Market open.
Full screen
Previous close0.7000
Open0.5500
Bid0.9000
Ask2.0000
Strike110.00
Expiry date2024-01-19
Day's range0.5500 - 0.7000
Contract rangeN/A
Volume3
Open interest424
  • GlobeNewswire

    Novartis Entresto receives positive CHMP opinion for pediatric heart failure

    If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric heart failure is an important cause of childhood morbidity and mortality – up to a third of all pediatric cardiac admissions are due to heart failure; these hospitalizations are associated with a 20-fold increase in the risk of death1,2 The positive opinion is based on final data from the 52-week Phase I

  • Zacks

    Why Novartis (NVS) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

  • Motley Fool

    What Bear Market? These 2 Winning Stocks Are Still Worth Buying.

    The stock market is in a precarious place. The sharp rise in both interest rates and bond yields has weighed heavily on most stocks since the first quarter of 2022. The top-shelf drugmakers Novartis (NYSE: NVS) and Vertex Pharmaceuticals (NASDAQ: VRTX) are two prime examples.